Biliary tract carcinoma – Clinical study on CAP7.1 as a treatment of biliary tract carcinomas

This site is designed for physicians and patients who are dealing with or are affected by carcinoma of the biliary system.
If you are affected by biliary tract carcinomas, you may be eligible to participate in a clinical study of CAP7.1, a new chemotherapeutic agent in phase II clinical development.

Participants with biliary tract cancer

Our aim is to recruit more participants with biliary tract cancer to the study, which is being conducted in several centers throughout Germany. If you are interested in participating in the clinical study, details can be found here. Please note that CAP7.1 is a study drug only and has not yet approved. It cannot be prescribed outside this clinical study of biliary tract cancer or be otherwise acquired commercially.